CStone Pharmaceuticals (2616) H1 2026 earnings summary

Executive summary

• Revenue surged 315.2% year-over-year to RMB205.1 million, driven by strong pharmaceutical sales, especially pralsetinib after NRDL inclusion and robust performance of other commercial products.

• Loss for the period narrowed to RMB252.3 million, a decrease of RMB17.9 million year-over-year, as gross profit replaced gross loss despite higher R&D and marketing expenses.

• Advanced Pipeline 2.0 with key clinical milestones, including Phase I/II data for CS2009 and first-in-human studies for CS5007.

• Expanded global commercialization footprint for sugemalimab, now approved in over 60 countries, with new partnerships in Oceania.

• Maintained a solid cash position with cash and equivalents at RMB1,560.2 million as of June 30, 2026, following a successful public offering.

Financial highlights

• Total revenue reached RMB205.1 million in H1 2026, up 315.2% year-over-year; pharmaceutical sales RMB183.2 million, license fees RMB6.9 million, royalties RMB15.0 million.

• Cost of revenue was RMB110.9 million, down from RMB142.2 million YoY due to prior year inventory write-downs.

• R&D expenses increased 95.4% YoY to RMB205.5 million, mainly from clinical trial costs.

• Net loss (Non-IFRS/adjusted) narrowed by 13% YoY to RMB230.9 million.

• Gross profit reached RMB94.2 million, reversing a gross loss of RMB92.8 million YoY.

Outlook and guidance

• Plans to initiate global Phase III trials for CS2009 in NSCLC and CRC by year-end 2026.

• Continued expansion of proprietary ADC and multispecific antibody platforms, with multiple candidates advancing toward clinical development.

• Ongoing discussions with multinational companies for further global partnerships and regulatory engagement.